Financial Performance - Alliance reported Q3 2025 revenue of $438 million, a 14% year-over-year increase[41] - Adjusted EBITDA for Q3 2025 was $111 million, up 16% year-over-year[41] - The Adjusted EBITDA margin was 253% in Q3 2025, a 40 bps increase year-over-year[41] - Adjusted net income for Q3 2025 increased by 47% year-over-year to $48 million[41] - For the first nine months of 2025, revenue reached $1274 billion, a 14% increase compared to the same period in 2024[41] - Adjusted EBITDA for the first nine months of 2025 was $330 million, a 13% increase year-over-year, with a margin of 259%[41] Segment Performance - North America's Q3 revenue grew by 14% year-over-year, reaching $331 million, with an Adjusted EBITDA of $95 million, a 13% increase[43, 45] - International Q3 revenue increased by 12% year-over-year to $107 million, with Adjusted EBITDA growing by 9% to $26 million[51] - For the first nine months of 2025, North America's revenue was $952 million, a 16% increase, and International revenue was $322 million, a 10% increase[47, 53] Balance Sheet and Capital Allocation - The company deleveraged to 31x IPO adjusted net leverage[41, 58] - IPO proceeds of $506 million were used to repay $525 million of debt, with an additional $135 million voluntary paydown in Q3[40, 59] - Debt repricing and paydowns are expected to deliver approximately $46 million in annualized interest savings[40, 59]

Q3 2025 Business Update and Financial Results November 13 2025 This document contains data pertaining to the Company's potential markets and the industry and environment in which it operates. Some of this data comes from external sources that are recognized in the field or from Company's estimates based on such sources. This presentation discusses product candidates that are under clinical development, and which have not yet been approved for marketing by the U.S. Food and Drug Administration or the Europea ...

Financial Performance - Q3 2024 - Net revenues for Q3 2024 were $118.292 million, compared to $132.037 million in Q3 2023[28] - Net loss for Q3 2024 was $15.366 million, compared to a net income of $(56.204) million in Q3 2023[28] - Adjusted EBITDA for Q3 2024 was $(12.106) million, compared to $(11.475) million in Q3 2023[28] - Adjusted EBITDA margin for Q3 2024 was (10.2)%, compared to (8.7)% in Q3 2023[28] Financial Performance - YTD 2024 - Net revenues for the nine months ended September 30, 2024, were $409.762 million, compared to $457.974 million for the same period in 2023[28] - Net loss for the nine months ended September 30, 2024, was $(65.294) million, compared to $(148.976) million for the same period in 2023[28] - Adjusted EBITDA for the nine months ended September 30, 2024, was $2.480 million, compared to $18.091 million for the same period in 2023[28] - Adjusted EBITDA margin for the nine months ended September 30, 2024, was 0.6%, compared to 4.0% for the same period in 2023[28] Financial Performance - TTM - TTM net revenues as of Q3 2024 were $686.459 million, compared to $527.350 million as of Q3 2023[32] - TTM net loss as of Q3 2024 was $(67.588) million, compared to $(299.713) million as of Q3 2023[32] - TTM Adjusted EBITDA as of Q3 2024 was $59.480 million, compared to $(76.690) million as of Q3 2023[32] - TTM Adjusted EBITDA margin as of Q3 2024 was 8.7%, compared to (14.5)% as of Q3 2023[32]

Acquisition of Mersana Therapeutics N O V E M B E R 2 0 2 5 Day One's Mission Inspired by the urgent needs of children, Day One creatively and intentionally develops new medicines for people of all ages with life- threatening diseases Q&A Session All Participants 2 Confidential Information. For internal use only. Forward Looking Statements This communication contains forward-looking statements. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", ...

Canadian Solar 3Q25 Earnings Call November 13, 2025 Canadian Solar Inc. Safe Harbor Statement This presentation has been prepared by the Company solely to facilitate the understanding of the Company's business model and growth strategy. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or t ...

Financial Performance - Core EPS increased by 16% to $1.16, compared to $1.00 in 3Q24[18, 33] - Core earnings increased by 10% to $2,035 million, compared to $1,828 million in 3Q24[30, 32] - Adjusted book value per share increased by 12% to $38.22, compared to $34.27 in 3Q24[18, 48] - New business CSM grew by 25% to $966 million, compared to $759 million in 3Q24[16, 29] - New business value increased by 11% to $906 million, compared to $806 million in 3Q24[16, 29] Business Segment Performance - Asia core earnings grew by 29% to $550 million (US dollars), driven by strong growth momentum[25, 36] - Global WAM core earnings increased by 9% to $525 million (Canadian dollars), supported by AUMA growth and expense management[39] - Canada APE sales increased by 9% to $374 million[42] Capital Management - The company's LICAT ratio was 138%[18, 53] - The financial leverage ratio decreased to 22.7%[18, 53]

Financial Performance & Outlook - Alvotech revised its FY2025 revenue outlook to $570-600 million, compared to the previous $600-700 million[20, 25, 72] - Adjusted EBITDA for FY2025 is revised to $130-150 million, down from the earlier $200-280 million[20, 25, 72] - Total revenues for 9M25 reached $420 million, a 24% increase year-over-year compared to 9M24[53, 54, 58] - Licensing revenues are expected to contribute $250-300 million annually until 2030[25] - The company's cash balance as of September 30, 2025, was $43 million[53, 54, 61] Product Pipeline & Approvals - The FDA issued a Complete Response Letter (CRL) for AVT05 (biosimilar to Simponi®) due to unresolved issues identified during a July inspection[20, 21, 22] - The Reykjavik manufacturing facility remains FDA approved for commercialized products like bHumira and bStelara[20, 22] - Approvals and/or positive CHMP opinions have been received for AVT06 (bEylea), AVT05 (bSimponi), and AVT03 (bProlia/Xgeva) by EMA and Japan's PMDA[20, 22, 33] - Alvotech expects to be among the first to launch a bSimponi in the EU, UK, and Japan[22, 33] Market Performance - Alvotech's biosimilar to Humira (AVT02) holds the second-largest market share of Humira biosimilars in the U S[28] - In Europe, Alvotech's Humira biosimilar volumes continue to grow, with Hukyndra holding a top position in several EU10 markets and experiencing 12% QoQ growth for the last four consecutive quarters[28] - Alvotech is securing formulary coverage for its Stelara biosimilar (AVT04) in the U S, and holds a leading position in Europe with approximately 10% overall share of the total Stelara market[20, 28]

Investor Relations Highlights 3Q25 Financial Indicators | | | | | | | R$ million | | --- | --- | --- | --- | --- | --- | --- | | Indicators Highlights | 3Q25 | 3Q24 | ∆% | 9M25 | 9M24 | ∆% | | Ebitda (R$ million) | 1,358.7 1,526.7 | | | -11.0 4,678.0 4,230.8 | | 10.6 | | Recurring Ebitda | 1,337.4 1,240.3 | | | 7.8 4,175.6 3,852.1 | | 8.4 | | Net Profit (R$ million) | 383.1 1,217.1 | | | -68.5 1,621.3 2,224.2 | | -27.1 | | Recuring Net Profit (R$ million) | 369.0 1,021.2 | | | -36.5 1,404.1 1,346.1 | | 4.3 ...

HPC/AI Infrastructure and Strategy - Bitfarms has a 1.9 GW power infrastructure asset portfolio in high-demand HPC/AI regions in North America, located in cool climates for improved efficiency[24] - The company is developing 18 MW of HPC/AI infrastructure at its Washington site for Nvidia Blackwell in 2026, with a secured supply chain for $128 million[26, 28] - Panther Creek in Eastern Pennsylvania is planned as a flagship HPC/AI campus with over 410 MW of power and 316 acres of land, with Phase 1 (50 MW) expected in H1 2027 and Phase 2 (300 MW) in H2 2027[33, 34] - Bitfarms has 170 MW of hydropower operating across multiple sites in Quebec, with potential to convert BTC mining infrastructure to HPC/AI[38] - Scrubgrass is a potential gigacampus site with 1.3 GW capacity and 650 acres, offering proximity to Pittsburgh and Cleveland[39, 40] Financial Performance and Capitalization - Bitfarms reported ~$8 million in monthly free cash flow from BTC mining operations in Q3 2025[49] - Q3 2025 revenue was $69 million, a 11% increase Q/Q and a 900% increase Y/Y[51] - Adjusted EBITDA for Q3 2025 was $20 million, a 122% increase Q/Q[51] - The company has over $1 billion in cash and Bitcoin on hand, with remaining funds available from the Macquarie facility[55] Strategic Initiatives - Bitfarms is undergoing a U S pivot, with the majority of planned MW development based in the U S , a new NYC office, and a transition to U S GAAP accounting, aiming for U S redomicile in 2026[42] - The company is evaluating a cloud monetization strategy for its Washington site to replace BTC mining cash flows[42]

Corporate Overview - As of September 30, 2025, Aldeyra's cash, cash equivalents, and marketable securities totaled $75.3 million, expected to fund the company into the second half of 2027[7] - Aldeyra is developing reproxalap for dry eye disease and allergic conjunctivitis, ADX-248 for obesity/hypertriglyceridemia and CNS/Neuroinflammatory Disease, ADX-246 for Dry Age-Related Macular Degeneration/Geographic Atrophy, and ADX-2191 for Primary Vitreoretinal Lymphoma and Retinitis Pigmentosa[6] RASP Modulation and ADX-629 - Reactive Aldehyde Species (RASP) modulation represents a novel pharmacology that may allow for control of protein systems, without turning any single protein on or off[16] - ADX-629, a first-generation RASP modulator, demonstrated activity in Phase 2 clinical trials, including statistically significant changes in lipid profiles (HDL, LDL/HDL ratio, FFA) and reduction of C-Reactive Protein in Alcohol-Associated Hepatitis[21, 29, 35] ADX-246 and ADX-248 - ADX-246, by binding the RASP retinaldehyde, potentially represents a new intravitreally administered therapy for the treatment of Dry Age-Related Macular Degeneration (Dry AMD), showing a reduction in toxic retinaldehyde metabolite A2E in an Abcr Knockout Mouse model[41, 42] - ADX-248, by binding HNE, a pro-inflammatory RASP, potentially represents a new orally administered therapy for the treatment of immune-mediated disease, demonstrating cytokine reduction in LPS-Challenged Mice and improved Epidermal Erosion Score in an Oxazolone Mouse Model of Atopic Dermatitis[44, 45] - ADX-248 significantly improved Rotarod Performance and Grip Strength in the Mouse MPTP Parkinson's Disease Model, as well as Wire Hang Time in the Rat 6-OHDA Parkinson's Disease Model[61, 69] - ADX-248 significantly improved Grip Strength and Rotarod Performance in the Mouse SOD1-G93A Amyotrophic Lateral Sclerosis Disease Model[72] Reproxalap - Reproxalap represents a novel potential therapeutic approach in Dry Eye Disease with rapid activity observed in clinical trials, with a PDUFA Target Action Date of December 16, 2025[85, 89] - The Phase 3 Dry Eye Chamber Trial achieved the primary endpoint of ocular discomfort (P=0.002 for Prespecified Analysis and P=0.004 for Post-Hoc Treatment Chamber Analysis)[87, 88] - Aldeyra has entered into an exclusive option agreement with AbbVie Inc for license to develop and commercialize Reproxalap, including a potential upfront payment of $100 million less option fees, a $100 million milestone payment upon U S FDA approval in dry eye disease, and $200 million in additional regulatory and commercial milestones[95, 97]